Literature DB >> 22258694

TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.

Serena Materazzi1, Camilla Fusi, Silvia Benemei, Pamela Pedretti, Riccardo Patacchini, Bernd Nilius, Jean Prenen, Christophe Creminon, Pierangelo Geppetti, Romina Nassini.   

Abstract

Paclitaxel produces a sensory neuropathy, characterized by mechanical and cold hypersensitivity, which are abated by antioxidants. The transient receptor potential vanilloid 4 (TRPV4) channel has been reported to contribute to paclitaxel-evoked allodynia in rodents. We recently showed that TRP ankyrin 1 (TRPA1) channel mediates oxaliplatin-evoked cold and mechanical allodynia, and the drug targets TRPA1 via generation of oxidative stress. Here, we have explored whether TRPA1 activation contributes to paclitaxel-induced mechanical and cold hypersensitivity and whether this activation is mediated by oxidative stress generation. Paclitaxel-evoked mechanical allodynia was reduced partially by the TRPA1 antagonist, HC-030031, and the TRPV4 antagonist, HC-067047, and was completely abated by the combination of the two antagonists. The reduced paclitaxel-evoked mechanical allodynia, observed in TRPA1-deficient mice, was completely abolished when mice were treated with HC-067047. Cold allodynia was abated completely by HC-030031 and in TRPA1-deficient mice. Exposure to paclitaxel of slices of mouse esophagus released the sensory neuropeptide, calcitonin gene-related peptide (CGRP). This effect was abolished by capsaicin desensitization and in calcium-free medium (indicating neurosecretion from sensory nerve terminals), partially reduced by either HC-030031 or HC-067047, and completely abated in the presence of glutathione (GSH). Finally, the reduced CGRP release, observed in esophageal slices of TRPA1-deficient mice, was further inhibited by GSH. Paclitaxel via oxygen radical formation targets TRPA1 and TRPV4, and both channels are key for the delayed development of mechanical allodynia. Cold allodynia is, however, entirely dependent on TRPA1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258694     DOI: 10.1007/s00424-011-1071-x

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  43 in total

Review 1.  Sensory detection and responses to toxic gases: mechanisms, health effects, and countermeasures.

Authors:  Bret F Bessac; Sven-Eric Jordt
Journal:  Proc Am Thorac Soc       Date:  2010-07

2.  Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice.

Authors:  Punam Gauchan; Tsugunobu Andoh; Atsushi Kato; Yasushi Kuraishi
Journal:  Neurosci Lett       Date:  2009-04-16       Impact factor: 3.046

3.  Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation.

Authors:  Romina Nassini; Maarten Gees; Selena Harrison; Gaetano De Siena; Serena Materazzi; Nadia Moretto; Paola Failli; Delia Preti; Nicola Marchetti; Alberto Cavazzini; Francesca Mancini; Pamela Pedretti; Bernd Nilius; Riccardo Patacchini; Pierangelo Geppetti
Journal:  Pain       Date:  2011-04-09       Impact factor: 6.961

4.  A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation.

Authors:  N Vergnolle; N Cenac; C Altier; L Cellars; K Chapman; G W Zamponi; S Materazzi; R Nassini; W Liedtke; F Cattaruzza; E F Grady; P Geppetti; N W Bunnett
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain.

Authors:  Yi Dai; Shenglan Wang; Makoto Tominaga; Satoshi Yamamoto; Tetsuo Fukuoka; Tomohiro Higashi; Kimiko Kobayashi; Koichi Obata; Hiroki Yamanaka; Koichi Noguchi
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy.

Authors:  Sarah J L Flatters; Gary J Bennett
Journal:  Pain       Date:  2004-05       Impact factor: 6.961

7.  Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Authors:  David Cella; Amy Peterman; Stacie Hudgens; Kimberly Webster; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

9.  Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1.

Authors:  Serena Materazzi; Romina Nassini; Eunice Andrè; Barbara Campi; Silvia Amadesi; Marcello Trevisani; Nigel W Bunnett; Riccardo Patacchini; Pierangelo Geppetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-07       Impact factor: 11.205

10.  Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat.

Authors:  Nicole Alessandri-Haber; Olayinka A Dina; Jenny J Yeh; Carlos A Parada; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

View more
  72 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

Review 2.  TRPs and pain.

Authors:  Yi Dai
Journal:  Semin Immunopathol       Date:  2015-09-15       Impact factor: 9.623

Review 3.  Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Authors:  Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2020-06-03       Impact factor: 8.739

Review 4.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

5.  Tmem100 Is a Regulator of TRPA1-TRPV1 Complex and Contributes to Persistent Pain.

Authors:  Hao-Jui Weng; Kush N Patel; Nathaniel A Jeske; Sonya M Bierbower; Wangyuan Zou; Vinod Tiwari; Qin Zheng; Zongxiang Tang; Gary C H Mo; Yan Wang; Yixun Geng; Jin Zhang; Yun Guan; Armen N Akopian; Xinzhong Dong
Journal:  Neuron       Date:  2015-01-29       Impact factor: 17.173

Review 6.  The transient receptor potential channel TRPA1: from gene to pathophysiology.

Authors:  Bernd Nilius; Giovanni Appendino; Grzegorz Owsianik
Journal:  Pflugers Arch       Date:  2012-09-22       Impact factor: 3.657

Review 7.  TRPA1 channels: molecular sentinels of cellular stress and tissue damage.

Authors:  Félix Viana
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

8.  Ethyl Vanillin Activates TRPA1.

Authors:  Shaw-Wen Wu; Daniel K Fowler; Forrest J Shaffer; Jonathon E M Lindberg; James H Peters
Journal:  J Pharmacol Exp Ther       Date:  2017-06-15       Impact factor: 4.030

9.  The peptide Phα1β, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice.

Authors:  Raquel Tonello; Camilla Fusi; Serena Materazzi; Ilaria M Marone; Francesco De Logu; Silvia Benemei; Muryel C Gonçalves; Elisabetta Coppi; Celio J Castro-Junior; Marcus Vinicius Gomez; Pierangelo Geppetti; Juliano Ferreira; Romina Nassini
Journal:  Br J Pharmacol       Date:  2016-11-28       Impact factor: 8.739

10.  The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives.

Authors:  Romina Nassini; Camilla Fusi; Serena Materazzi; Elisabetta Coppi; Tiziano Tuccinardi; Ilaria M Marone; Francesco De Logu; Delia Preti; Raquel Tonello; Alberto Chiarugi; Riccardo Patacchini; Pierangelo Geppetti; Silvia Benemei
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.